Main Points:
– Mallinckrodt and Endo are planning a merger worth $6.7 billion.
– The combined entity will have about 5,700 employees.
– They will possess 17 manufacturing facilities and 30 distribution centers.
– The majority of their operations will be in the United States, with facilities also in Europe, India, Australia, and Japan.
Author’s Take:
The merger between Mallinckrodt and Endo, valued at $6.7 billion, will create a substantial entity in the pharmaceutical industry. With a significant workforce and a global operational presence, this move is poised to have a notable impact on the market dynamics and the competitive landscape within the sector.
Click here for the original article.